Cas:1365545-48-7 (4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide manufacturer & supplier

Chemical Name:(4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

CAS.NO:1365545-48-7

Synonyms:1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-6a-methyl-2-oxo-, (4bS,6aS,7S,9aS,9bS)-;(4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide;Dutasteride Impurity 19

Molecular Formula:C₂₆H₂₆F₆N₂O₂

Molecular Weight:512.487

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:653.8±55.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.557

PSA:

Exact Mass:512.189819

LogP:5.27

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-6a-methyl-2-oxo-, (4bS,6aS,7S,9aS,9bS)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dutasteride Impurity 19 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-6a-methyl-2-oxo-, (4bS,6aS,7S,9aS,9bS)- Use and application,Dutasteride Impurity 19 technical grade,usp/ep/jp grade.

Related News: Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. (4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide manufacturer A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. (4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide supplier In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. (4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide vendor The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant��s collection. (4bS,6aS,7S,9aS,9bS)-N-[2,5-Bis(trifluoromethyl)phenyl]-6a-methyl-2-oxo-2,4b,5,6,6a,7,8,9,9a,9b,10,11-dodecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide factory Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.